INT82829

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.78
First Reported 1999
Last Reported 2010
Negated 1
Speculated 3
Reported most in Body
Documents 104
Total Number 120
Disease Relevance 57.00
Pain Relevance 9.81

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

extracellular space (COMP) extracellular region (COMP) cell adhesion (COMP)
proteinaceous extracellular matrix (COMP)
Anatomy Link Frequency
cartilage 21
chondrocytes 12
ligament 5
tendons 4
knee 3
COMP (Homo sapiens)
Pain Link Frequency Relevance Heat
Osteoarthritis 622 100.00 Very High Very High Very High
rheumatoid arthritis 272 100.00 Very High Very High Very High
Arthritis 756 99.38 Very High Very High Very High
psoriasis 266 99.28 Very High Very High Very High
metalloproteinase 17 99.24 Very High Very High Very High
Pain 104 98.64 Very High Very High Very High
Inflammation 138 98.48 Very High Very High Very High
imagery 155 95.24 Very High Very High Very High
cytokine 21 88.08 High High
Mechanotransduction 26 80.52 Quite High
Disease Link Frequency Relevance Heat
Osteochondrodysplasias 630 100.00 Very High Very High Very High
Osteoarthritis 595 100.00 Very High Very High Very High
Targeted Disruption 522 100.00 Very High Very High Very High
Cytomegalovirus Infection 410 100.00 Very High Very High Very High
Rheumatoid Arthritis 273 100.00 Very High Very High Very High
Osteophyte 131 99.96 Very High Very High Very High
Frailty 6 99.92 Very High Very High Very High
Chondrosarcoma 780 99.84 Very High Very High Very High
Disease 540 99.62 Very High Very High Very High
Seronegative Spondarthritis 574 99.38 Very High Very High Very High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
By 2 days shRNA 3B reduced COMP protein levels by 90%, and COMP expression was not detectable after 4 days of culture (Fig. 4*) (only MT-COMP results are shown in Fig. 4 because WT-COMP knock down was identical). shRNA 3A was approximately three times less efficient than 3B at reducing COMP protein levels.
Gene_expression (expression) of COMP associated with targeted disruption
1) Confidence 0.78 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2858657 Disease Relevance 0.60 Pain Relevance 0
This result shows that shRNA 3B was equally effective at reducing a wide range of COMP mRNA expression levels.


Gene_expression (expression) of COMP mRNA
2) Confidence 0.78 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2858657 Disease Relevance 0.12 Pain Relevance 0
Using a DOX-inducible system, we tested shRNA 3B against varying levels of COMP expression.
Gene_expression (expression) of COMP
3) Confidence 0.78 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2858657 Disease Relevance 0.35 Pain Relevance 0
We next asked if shRNA 3B would be effective against high levels of COMP expression.
Gene_expression (expression) of COMP
4) Confidence 0.78 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2858657 Disease Relevance 0.44 Pain Relevance 0
Moreover, in both COS-7 and RCS cells, shRNA 3B reduced the elevated CRT levels that result from the overexpression of COMP.
Gene_expression (overexpression) of COMP associated with chondrosarcoma
5) Confidence 0.78 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2858657 Disease Relevance 0.41 Pain Relevance 0
Knock down was observed with all levels of COMP expression suggesting that shRNA 3B was effective even when target mRNA levels are high and therapeutic intervention would be most needed (Fig. 5).
Gene_expression (expression) of COMP associated with targeted disruption
6) Confidence 0.78 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2858657 Disease Relevance 0.36 Pain Relevance 0
Overall, we show that suppression of COMP expression by RNAi in vitro would be an effective treatment modality for the PSACH and MED/EDM1 chondrocyte pathology.
Gene_expression (expression) of COMP in chondrocyte
7) Confidence 0.78 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2858657 Disease Relevance 0.46 Pain Relevance 0
Primary human chondrocytes were used to demonstrate the effectiveness of shRNA against endogenously expressed COMP.
Gene_expression (expressed) of COMP in chondrocytes
8) Confidence 0.78 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2858657 Disease Relevance 0.34 Pain Relevance 0.03
shRNAs maintain long-term knock down in the presence of high levels of COMP expression
Gene_expression (expression) of COMP associated with targeted disruption
9) Confidence 0.78 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2858657 Disease Relevance 0.88 Pain Relevance 0
In this set of experiments, we used the tetracycline induced MT-COMP adenovirus and varied the dose of doxycycline (DOX) to attain high levels of COMP expression.
Gene_expression (expression) of COMP
10) Confidence 0.78 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2858657 Disease Relevance 0.26 Pain Relevance 0
COS-7 cells were used to screen and assess the ability of individual shRNAs to reduce COMP expression.
Gene_expression (expression) of COMP
11) Confidence 0.78 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2858657 Disease Relevance 0.35 Pain Relevance 0.03
Quantitative RT-PCR for expression of collagen type I (COL1A1), collagen type III (COL3A1), cartilage oligomeric matrix protein (COMP), decorin, matrix metalloproteinase-3 (MMP-3), and matrix metalloproteinase-13 (MMP-13) was performed as were DNA and total soluble collagen assays.
Gene_expression (expression) of COMP in cartilage associated with metalloproteinase
12) Confidence 0.75 Published 2007 Journal J. Orthop. Res. Section Abstract Doc Link 17106885 Disease Relevance 0 Pain Relevance 0.16
Quantitative RT-PCR for expression of collagen type I (COL1A1), collagen type III (COL3A1), cartilage oligomeric matrix protein (COMP), decorin, matrix metalloproteinase-3 (MMP-3), and matrix metalloproteinase-13 (MMP-13) was performed as were DNA and total soluble collagen assays.
Gene_expression (expression) of cartilage oligomeric matrix protein in cartilage associated with metalloproteinase
13) Confidence 0.75 Published 2007 Journal J. Orthop. Res. Section Abstract Doc Link 17106885 Disease Relevance 0 Pain Relevance 0.16
Moreover, these findings also suggest that surpressing intracellular retention of mutant COMP by reducing COMP expression could be used as a therapeutic approach.
Gene_expression (expression) of COMP
14) Confidence 0.68 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2858657 Disease Relevance 0.53 Pain Relevance 0.04
RNAi Reduces Expression and Intracellular Retention of Mutant Cartilage Oligomeric Matrix Protein

Mutations in cartilage oligomeric matrix protein (COMP), a large extracellular glycoprotein expressed in musculoskeletal tissues, cause two skeletal dysplasias, pseudoachondroplasia and multiple epiphyseal dysplasia.

Gene_expression (expressed) of COMP in cartilage associated with osteochondrodysplasias
15) Confidence 0.68 Published 2010 Journal PLoS ONE Section Title Doc Link PMC2858657 Disease Relevance 0.42 Pain Relevance 0
Preventing or reducing PSACH cellular pathology will require long-term reduction of COMP expression because chondrocytes produce COMP throughout life [2], [17], [18].
Gene_expression (produce) of COMP in chondrocytes
16) Confidence 0.68 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2858657 Disease Relevance 0.19 Pain Relevance 0.03
shRNAs efficiently reduce endogenous COMP expression in human growth plate chondrocytes
Gene_expression (expression) of COMP in chondrocytes
17) Confidence 0.68 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2858657 Disease Relevance 0.06 Pain Relevance 0
We have previously shown that MT-COMP expression induces the intracellular retention of ECM proteins and formation of intracellular matrix [9], [10].
Gene_expression (expression) of MT-COMP
18) Confidence 0.68 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2858657 Disease Relevance 0.20 Pain Relevance 0
The experiment was terminated after two weeks because COS-7 replication and viral degradation diluted the adenoviral COMP expression to very low levels.
Gene_expression (expression) of COMP
19) Confidence 0.68 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2858657 Disease Relevance 0.61 Pain Relevance 0
COMP is expressed at low levels when human primary chondrocytes are cultured in monolayer.
Gene_expression (expressed) of COMP in chondrocytes
20) Confidence 0.68 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2858657 Disease Relevance 0 Pain Relevance 0

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox